|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010798,
umls-concept:C0011082,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0022885,
umls-concept:C0028420,
umls-concept:C0031327,
umls-concept:C0031437,
umls-concept:C0039593,
umls-concept:C0070122,
umls-concept:C0441655,
umls-concept:C0444706,
umls-concept:C1882115
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2001-10-23
|
|
pubmed:abstractText |
The ultrarapid metabolizer phenotype of the cytochrome P4502D6 (CYP2D6) enzyme has been considered a relevant cause of nonresponse to antidepressant drug therapy. Prescribing high doses of antidepressants to such patients leads to high concentrations of potentially toxic metabolites and an increased risk for adverse reactions. Normalization of the metabolic status of ultrarapid metabolizers by inhibition of CYP2D6 activity could offer a clinically acceptable method to successfully treat such patients with antidepressants.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/10-hydroxynortriptyline,
http://linkedlifedata.com/resource/pubmed/chemical/4-hydroxydebrisoquin,
http://linkedlifedata.com/resource/pubmed/chemical/Antidepressive Agents, Tricyclic,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP2D6,
http://linkedlifedata.com/resource/pubmed/chemical/Debrisoquin,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Mixed Function Oxygenases,
http://linkedlifedata.com/resource/pubmed/chemical/Nortriptyline,
http://linkedlifedata.com/resource/pubmed/chemical/Paroxetine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
327-35
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11673748-Adult,
pubmed-meshheading:11673748-Antidepressive Agents, Tricyclic,
pubmed-meshheading:11673748-Cytochrome P-450 CYP2D6,
pubmed-meshheading:11673748-Debrisoquin,
pubmed-meshheading:11673748-Drug Combinations,
pubmed-meshheading:11673748-Drug Interactions,
pubmed-meshheading:11673748-Enzyme Inhibitors,
pubmed-meshheading:11673748-Female,
pubmed-meshheading:11673748-Humans,
pubmed-meshheading:11673748-Hypotension, Orthostatic,
pubmed-meshheading:11673748-Male,
pubmed-meshheading:11673748-Middle Aged,
pubmed-meshheading:11673748-Mixed Function Oxygenases,
pubmed-meshheading:11673748-Nortriptyline,
pubmed-meshheading:11673748-Paroxetine,
pubmed-meshheading:11673748-Phenotype,
pubmed-meshheading:11673748-Tremor,
pubmed-meshheading:11673748-Xerostomia
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
|
|
pubmed:affiliation |
Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden. karlai@utu.fi
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
